Caribou Biosciences Reports Q1 2025 Financial Results

Summary

Caribou Biosciences announced their Q1 2025 financial results, reporting a net loss of $40 million, improving from a $41.2 million loss in Q1 2024. Licensing revenue remained stable at $2.4 million. R&D expenses increased to $35.5 million, while general and administrative expenses decreased to $9.7 million. The company holds $212.5 million in cash and equivalents, projected to sustain operations until mid-2027. Caribou plans to release clinical data from its oncology project in H2 2025. Reuters

Impact Analysis

1. Business Overview Analysis